Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Passes Above 200 Day Moving Average – Should You Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $47.89 and traded as high as $55.17. Global X Genomics & Biotechnology ETF shares last traded at $54.83, with a volume of 25,295 shares trading hands.

Global X Genomics & Biotechnology ETF Price Performance

The business’s fifty day moving average price is $51.30 and its 200-day moving average price is $47.89. The stock has a market capitalization of $83.89 million, a price-to-earnings ratio of -23.43 and a beta of 1.16.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently declared a dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were issued a dividend of $0.0579 per share. The ex-dividend date was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is -27.35%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Large investors have recently made changes to their positions in the business. Jane Street Group LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares in the last quarter. Sei Investments Co. grew its stake in Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after acquiring an additional 12,105 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the period. IFP Advisors Inc increased its holdings in Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after acquiring an additional 489 shares during the period. Finally, U.S. Capital Wealth Advisors LLC purchased a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter worth approximately $575,000. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.